MediLink, Roche partner to develop next-gen oncology candidate YL211
Roche will obtain exclusive global rights to develop, manufacture, and commercialise MediLink’s cancer drug candidate YL211, in exchange…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
03 Jan 24
Roche will obtain exclusive global rights to develop, manufacture, and commercialise MediLink’s cancer drug candidate YL211, in exchange…
03 Jan 24
The collaboration is aimed at creating cloud-based clinical software tools that facilitate comprehensive decision-making for early-stage breast cancer…
03 Jan 24
Voyager and Novartis Pharma will work on potential gene therapies for Huntington’s disease and spinal muscular atrophy using…
03 Jan 24
Slimaglutide is a weight management supplement that uses 10 GLP-1 Receptor agonists and secretagogues to offer a natural…
03 Jan 24
In preclinical animal trials, the asset showed an excellent safety profile, quick and widespread biodistribution throughout the brain,…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
03 Jan 24
Issuance of U.S. Patent No. 11,850,053 also covers a novel system and method for calculating accurate, real-time heart…
03 Jan 24
The aim of the collaboration is to develop cloud-based clinical software tools that will support the end-to-end decision-making…
03 Jan 24
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a significant expansion of its business in the Middle…
03 Jan 24
According to the CDC, Cognitive Decline a Major Health Concern for 11% of Americans, 68.59 Million Now Between…
03 Jan 24
Apollo Therapeutics is a portfolio biopharmaceutical company focused on translating fundamental medical research into medicines